Form 4: Medpace CEO Sells $34M in Stock

Medpace Holdings CEO August J. Troendle reported direct sales of 56,482 shares of common stock totaling approximately $34.09 million in late November 2025.

Summary

• August J. Troendle, CEO, Director, and 10% Owner of Medpace Holdings, Inc. (MEDP), reported direct sales of common stock.
• On November 26, 2025, Troendle sold 41,331 shares at a weighted average price of $606.88 per share, totaling approximately $25,099,990.
• On November 28, 2025, an additional 15,151 shares were sold at a weighted average price of $593.46 per share, totaling approximately $8,990,000.
• These transactions were executed pursuant to a limit order placed by the Reporting Person during an open window period, indicating a pre-planned sale.
• Following these direct sales, Troendle directly beneficially owns 675,728 shares of Medpace common stock.
• Troendle also indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he is the sole manager and controlling unit holder, disclaiming beneficial ownership except for his pecuniary interest.

Sentiment

Score: 4

Explanation: The sale of a significant number of shares by a CEO and 10% owner, even if pre-planned, can be perceived as a slight negative by the market, potentially indicating that the insider believes the stock is fully valued or that they are diversifying their holdings.

Negatives

• Insider selling, especially by a CEO and 10% owner, can sometimes be perceived negatively by the market, potentially signaling a lack of confidence or a belief that the stock is fully valued.
• The total value of shares sold is significant, approximately $34.09 million.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

Industry Context

This filing reports an individual's stock transaction and does not provide broader industry context. Medpace Holdings operates in the clinical research organization (CRO) sector, providing clinical development services to the pharmaceutical, biotechnology, and medical device industries.

Corporate Governance

Related Party Transactions

• August J. Troendle indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he is the sole manager and controlling unit holder. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal regarding the stock's valuation or future prospects, potentially leading to increased scrutiny or selling pressure on the stock.

Key Dates

Keywords

Medpace Holdings, MEDP, August J. Troendle, Insider Sale, Form 4, CEO Stock Sale, Beneficial Ownership, Equity Transaction, Clinical Research Organization